Shots:
- The P-ll RESTORE-1 study involves assessing NBIb-1817(VY-AADC) for the treatment of Parkinson’s disease. Neuroscience & Voyager will closely work with FDA & DCMB to determine the next clinical trial for RESTORE-1
- DSMB request a clinical hold, follows the IND Safety Report submit by Neurocrine Biosciences related to the observation of MRI abnormalities in some RESTORE-1 study participants and requested additional patient-level data from the trial and plans to review data in early 2021
- NBIb-1817 is an investigational recombinant AAV serotype 2 vectors encoding the gene for human AADC help to produce AADC enzyme in brain cells & convert levodopa to dopamine
Click here to read full press release/ article | Ref: GlobeNewswire | Image: PR Newswire
The post Voyager Therapeutics Provides Update on NBIB-1817(VY-AADC) Program to Treat Parkinson Disease first appeared on PharmaShots.
